Nicox SA provided provides financial guidance for the year ended December 31, 2017. At the end of December 2017, the estimated net loss of the group amounts to €3.6 million. This estimated net loss includes the European commercial business which is treated as Discontinued Operations since their transfer in August 2016. The Group had estimated cash, cash equivalents and financial instruments of €41.4 million as of December 31, 2017. Estimated net revenue was €2.3 million, which is comprised exclusively of the U.S.FDA approval milestone payment from Bausch + Lomb, and royalty revenue following the launch of VYZULTATM in the second half of December 2017, after deduction of Nicox's milestone and royalty payments to Pfizer under a previous agreement signed in 2009. Operating loss before changes in fair value of contingent consideration expected to be $17,534,000; operating loss expected to be $18,518,000; and loss before tax from continuing operations expected to be $19,112,000. The group reported a net loss from continued operations of €8.3 million as of December 2017, compared to a net loss of €6.7 million at the same date in 2016. The net loss for 2017 have been significantly reduced due to the non-cash impact of the reduction of deferred tax liability related to Nicox Ophthalmics Inc. following the new US tax law voted in December 2017 decreasing significantly the federal corporate tax rate. The 2016 loss was significantly decreased by the non-cash impact of the reduction in the value of a potential earn-out payable in shares to Nicox Ophthalmics Inc. former shareholders. Notes: MS Health Analytics 2016 reported sales and TRx (Total Prescriptions) IMS Health Analytics and TRx (Total Prescriptions), not including OTC products for ocular allergy Internal estimate based on IMS Health Analytics data.